₹-0.15
(Market cap
₹11 Cr
Recently Viewed
Clear AllMarket cap
₹11 Cr
Revenue (TTM)
₹19 Cr
P/E Ratio
850.5
P/B Ratio
1.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹0 Cr
ROE
6.3 %
ROCE
10.2 %
Industry P/E
59.64
EV/EBITDA
9.7
Debt to Equity
0.4
Book Value
₹18.3
EPS
₹0
Face value
10
Shares outstanding
5,071,700
CFO
₹9.29 Cr
EBITDA
₹11.03 Cr
Net Profit
₹3.61 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Beryl Drugs
| -6.8 | 18.5 | -0.8 | 3.2 | 17.6 | 30.3 | -4.0 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Beryl Drugs
| -35.1 | 60.3 | 70.1 | 7.3 | 45.6 | 60.9 | -48.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Beryl Drugs
|
21.8 | 11.1 | 19.1 | 0.0 | 0.9 | 0.1 | 850.5 | 1.2 |
| 2,594.1 | 21,258.3 | 1,339.4 | 356.4 | 33.2 | 23.2 | 59.7 | 12.9 | |
| 755.0 | 14,830.7 | 7,266.8 | 627.5 | 11.9 | 12.6 | 23.6 | 2.7 | |
| 699.7 | 17,327.2 | 5,365.6 | 595.0 | 16.6 | 13.3 | 29.1 | 3.4 | |
| 926.6 | 14,761.4 | 7,918.4 | 429.9 | 10.7 | 7.2 | 34.1 | 2.2 | |
| 1,095.8 | 19,627.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,738.1 | 19,938.7 | 1,419.3 | 20.1 | 8.4 | 0.5 | 991.9 | 3.4 | |
| 161.9 | 21,520.5 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.6 | |
| 467.7 | 18,887.7 | 3,738.7 | 316.7 | 12.5 | 7.5 | 59.6 | 3.9 | |
| 1,395.6 | 22,661.2 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1030.1 | 4.9 |
No Review & Analysis are available.
Beryl Drugs Limited manufactures and markets branded and generic pharmaceutical formulations in India. The company offers I.V. fluids and small volume injectables, as well as veterinary products. It also provides research and development, and... contract manufacturing services. Beryl Drugs Limited was founded in 1993 and is based in Indore, India. Read more
Incorporated
1993
Chairman
Sudhir Sethi
Managing Director
Sanjay Sethi
Headquarters
Indore, Madhya Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of Beryl Drugs Ltd is ₹21.80 (BSE) as of 30-Apr-2026 IST. Beryl Drugs Ltd has given a return of 17.61% in the last 3 years.
The P/E ratio of Beryl Drugs Ltd is 850.49 times as on 30-Apr-2026, a 1326 premium to its peers’ median range of 59.64 times.
The P/B ratio of Beryl Drugs Ltd is 1.19 times as on 30-Apr-2026, a 65 discount to its peers’ median range of 3.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.45
|
1.13
|
|
2024
|
19.35
|
1.67
|
|
2023
|
8.05
|
0.77
|
|
2022
|
0.00
|
0.73
|
|
2021
|
13.99
|
0.42
|
The 52-week high and low of Beryl Drugs Ltd are Rs 30.00 and Rs 15.92 as of 01-May-2026.
Beryl Drugs Ltd has a market capitalisation of ₹ 11 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Beryl Drugs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.